We are live on
!
Find out more
Jacobs Levy Equity Management Portfolio holdings
AUM
$23.8B
1-Year Est. Return
25.4%
This Fund
S&P 500
This Quarter
Est. Return
+9.96%
1 Year Est. Return
+25.4%
3 Year Est. Return
+87.35%
5 Year Est. Return
+125.75%
10 Year Est. Return
+515.94%
AUM
$25.2B
AUM Growth
-$335M
(-1.3%)
Cap. Flow
-$2.05B
Cap. Flow
% of AUM
-8.13%
Top 10 Holdings %
Top 10 Hldgs %
26.87%
Holding
1,147
New
127
Increased
298
Reduced
504
Closed
194
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alnylam Pharmaceuticals
ALNY
|
+$160M |
| 2 |
Masco
MAS
|
+$134M |
| 3 |
Lam Research
LRCX
|
+$112M |
| 4 |
Coupang
CPNG
|
+$101M |
| 5 |
Nu Holdings
NU
|
+$98.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
GE Vernova
GEV
|
+$205M |
| 2 |
Lennox International
LII
|
+$191M |
| 3 |
NVIDIA
NVDA
|
+$169M |
| 4 |
Tractor Supply
TSCO
|
+$157M |
| 5 |
Apple
AAPL
|
+$151M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 33.69% |
| 2 | Consumer Discretionary | 12.85% |
| 3 | Industrials | 12.71% |
| 4 | Financials | 12.68% |
| 5 | Healthcare | 9.5% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
726
The RMR Group
RMR
$343M
| $977K | ﹤0.01% |
62,118
-18,187
| -23% | -$304K |
|
727
Cactus
WHD
$3.69B
| $976K | ﹤0.01% |
24,739
| – | – |
|
728
Coca-Cola Consolidated
COKE
$13B
| $976K | ﹤0.01% |
8,331
-459
| -5% | -$53.2K |
|
729
Copart
CPRT
$28.4B
| $976K | ﹤0.01% |
21,694
-53,067
| -71% | -$2.5M |
|
|
AOMR
730
Angel Oak Mortgage REIT
AOMR
$223M
| $972K | ﹤0.01% |
103,757
+88,596
| +584% | +$848K |
|
731
United Therapeutics
UTHR
$26.1B
| $951K | ﹤0.01% |
2,268
-5,666
| -71% | -$1.91M |
|
732
Magnolia Oil & Gas
MGY
$5.55B
| $946K | ﹤0.01% |
39,630
-2,518
| -6% | -$60K |
|
733
Bioventus
BVS
$895M
| $943K | ﹤0.01% |
140,967
+4,605
| +3% | +$32K |
|
734
Lexicon Pharmaceuticals
LXRX
$1.04B
| $935K | ﹤0.01% |
+692,727
| New | +$786K |
|
|
FIRY
735
Firy Inc
FIRY
$154M
| $928K | ﹤0.01% |
116,052
+51,724
| +80% | +$398K |
|
736
Fortrea Holdings
FTRE
$1.96B
| $906K | ﹤0.01% |
+107,573
| New | +$823K |
|
737
Priority Technology Holdings
PRTH
$567M
| $900K | ﹤0.01% |
131,062
-85,283
| -39% | -$644K |
|
738
Foghorn Therapeutics
FHTX
$301M
| $900K | ﹤0.01% |
184,063
-8,600
| -4% | -$45.6K |
|
|
SW
739
Smurfit Westrock
SW
$26.6B
| $892K | ﹤0.01% |
20,962
-685
| -3% | -$31K |
|
740
Kyverna Therapeutics
KYTX
$455M
| $886K | ﹤0.01% |
+147,712
| New | +$591K |
|
741
Accuray
ARAY
$29M
| $874K | ﹤0.01% |
523,145
+179,745
| +52% | +$266K |
|
742
Benchmark Electronics
BHE
$2.76B
| $871K | ﹤0.01% |
22,582
+2,995
| +15% | +$118K |
|
743
WaFd
WAFD
$2.71B
| $867K | ﹤0.01% |
28,638
-22,682
| -44% | -$695K |
|
|
ALX
744
Alexander's
ALX
$1.36B
| $864K | ﹤0.01% |
+3,685
| New | +$866K |
|
745
Skyworks Solutions
SWKS
$9.73B
| $862K | ﹤0.01% |
11,197
-2,543
| -19% | -$189K |
|
746
CPI Card Group
PMTS
$243M
| $859K | ﹤0.01% |
56,745
+5,116
| +10% | +$90.9K |
|
|
AEVA
747
Aeva Technologies
AEVA
$1B
| $857K | ﹤0.01% |
+59,076
| New | +$1.12M |
|
748
Nektar Therapeutics
NKTR
$2.39B
| $850K | ﹤0.01% |
14,946
-133,294
| -90% | -$4.41M |
|
749
HEICO Corp
HEI
$50.8B
| $848K | ﹤0.01% |
2,628
-428
| -14% | -$136K |
|
750
AptarGroup
ATR
$8.8B
| $838K | ﹤0.01% |
6,270
-63,627
| -91% | -$9.2M |
|
Similar funds
OAG
CHP
SAM
JG
Jacobs Levy Equity Management's Q3 2025 Portfolio in Review
As of Q3 2025, Jacobs Levy Equity Management held 1,147 positions worth $25.2B, down 1.3% from $25.5B the previous quarter. Its ten largest holdings account for 27% of the portfolio.
Jacobs Levy Equity Management withdrew a net $2.05B in Q3 2025, closing 194 positions and reducing 504 holdings. Its most notable exit was Progressive, an estimated $66.7M position sold in full.
By sector, the portfolio is most concentrated in Technology at 34% of assets, up from 32% a quarter earlier, followed by Consumer Discretionary and Industrials.
Against the trend, Jacobs Levy Equity Management opened a new position in Bank of America worth $45M.
- Jacobs Levy Equity Management's largest Q3 2025 buy was Bank of America: 873,228 shares worth $45M.
- Jacobs Levy Equity Management added most to Alnylam Pharmaceuticals in Q3 2025, an estimated $160M increase.
- Jacobs Levy Equity Management's biggest Q3 2025 reduction was GE Vernova, cutting an estimated $205M.
- Jacobs Levy Equity Management fully exited Progressive in Q3 2025, selling an estimated $66.7M.
- Jacobs Levy Equity Management's ten largest holdings make up 27% of its $25.2B portfolio in Q3 2025.
- Jacobs Levy Equity Management opened 127 new positions and closed 194 in Q3 2025.
- Jacobs Levy Equity Management's portfolio value fell 1.3% quarter-over-quarter to $25.2B.
Based on Jacobs Levy Equity Management's 13F filing for Q3 2025, filed 17 Nov 2025.